Payment overview · 2025
General Payments
$904.28
46 reported records · 13 companies
Healthcare provider profile · identity verified
Brian W Wells, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BESSEMER, AL · NPI 1457666406
Verified facts
What the public records show
CMS Open Payments records show Brian W Wells, MD received $904.28 in general payments during 2025 across 46 reported records.
Dexcom, Inc. accounted for 19.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 198 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 328 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $178.38 | 19.7% | 8 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $177.00 | 19.6% | 11 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $144.07 | 15.9% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $111.17 | 12.3% | 6 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $93.36 | 10.3% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $56.01 | 6.2% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $30.55 | 3.4% | 2 | 2025 |
| Lexicon Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $26.38 | 2.9% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $21.93 | 2.4% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $17.98 | 2.0% | 1 | 2025 |
| La Jolla Pharmaceutical Company | Unresolved — no canonical attribution shown | $16.27 | 1.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.70 | 1.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $15.48 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $886.90 | 45 |
| Education | $17.38 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $178.38 | 8 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $144.07 | 6 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $115.00 | 8 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $111.17 | 6 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $75.98 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $62.00 | 3 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $58.70 | 3 | 2025 |
Source payment records
|
|||||
| NUCALA Normalized: nucala |
Biological | GlaxoSmithKline, LLC. | $38.26 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $30.55 | 2 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $21.93 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $17.98 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| ZEVTERA Normalized: zevtera |
Drug | La Jolla Pharmaceutical Company | $16.27 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.70 | 1 | 2025 |
Source payment records
|
|||||
| RELISTOR Normalized: relistor |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $15.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 328 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 29 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 198 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
94 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
48 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
198 | 30 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
328 | 49 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1028 | 260 |
| Amlodipine Besylate | Amlodipine Besylate | 824 | 216 |
| Gabapentin | Gabapentin | 678 | 118 |
| Levothyroxine Sodium | Levothyroxine Sodium | 600 | 136 |
| Pantoprazole Sodium | Pantoprazole Sodium | 526 | 126 |
| Lisinopril | Lisinopril | 413 | 111 |
| Losartan Potassium | Losartan Potassium | 405 | 110 |
| Metformin Hcl | Metformin Hcl | 403 | 87 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 395 | 96 |
| Hydrochlorothiazide | Hydrochlorothiazide | 391 | 107 |
| Omeprazole | Omeprazole | 390 | 100 |
| Furosemide | Furosemide | 388 | 120 |
| Montelukast Sodium | Montelukast Sodium | 346 | 90 |
| Pravastatin Sodium | Pravastatin Sodium | 331 | 86 |
| Eliquis | Apixaban | 328 | 49 |
| Trazodone Hcl | Trazodone Hcl | 309 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 300 | 83 |
| Carvedilol | Carvedilol | 294 | 75 |
| Methylprednisolone | Methylprednisolone | 261 | 184 |
| Metformin Hcl Er | Metformin Hcl | 219 | 55 |
| Simvastatin | Simvastatin | 214 | 58 |
| Meloxicam | Meloxicam | 213 | 60 |
| Clonazepam | Clonazepam | 201 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 201 | 46 |
| Ozempic | Semaglutide | 198 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 197 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 195 | 45 |
| Potassium Chloride | Potassium Chloride | 193 | 55 |
| Alprazolam | Alprazolam | 176 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 168 | 42 |
| Doxycycline Hyclate | Doxycycline Hyclate | 160 | 119 |
| Duloxetine Hcl | Duloxetine Hcl | 152 | 31 |
| Glimepiride | Glimepiride | 146 | 36 |
| Allopurinol | Allopurinol | 143 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 143 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 140 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 139 | 36 |
| Lorazepam | Lorazepam | 130 | 23 |
| Pregabalin | Pregabalin | 129 | 16 |
| Tramadol Hcl | Tramadol Hcl | 129 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 123 | 31 |
| Alendronate Sodium | Alendronate Sodium | 120 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 117 | 35 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 114 | 28 |
| Sertraline Hcl | Sertraline Hcl | 105 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 101 | 40 |
| Famotidine | Famotidine | 97 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 94 | 23 |
| Spironolactone | Spironolactone | 82 | 21 |
| Paroxetine Hcl | Paroxetine Hcl | 78 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 78 | 18 |
| Donepezil Hcl | Donepezil Hcl | 77 | 17 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 74 | 64 |
| Clonidine Hcl | Clonidine Hcl | 68 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 66 | suppressed |
| Memantine Hcl | Memantine Hcl | 66 | 11 |
| Nystatin | Nystatin | 66 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 65 | 14 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 65 | 18 |
| Sucralfate | Sucralfate | 65 | 19 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 64 | 20 |
| Buspirone Hcl | Buspirone Hcl | 63 | 15 |
| Methocarbamol | Methocarbamol | 63 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 63 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 62 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 58 | 13 |
| Finasteride | Finasteride | 57 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 55 | 17 |
| Januvia | Sitagliptin Phosphate | 55 | 15 |
| Ibuprofen | Ibuprofen | 54 | 13 |
| Levetiracetam | Levetiracetam | 53 | 11 |
| Atenolol | Atenolol | 52 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 12 |
| Benazepril Hcl | Benazepril Hcl | 51 | 12 |
| Jardiance | Empagliflozin | 51 | 13 |
| Synthroid | Levothyroxine Sodium | 51 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 50 | 12 |
| Chlorthalidone | Chlorthalidone | 50 | 14 |
| Ezetimibe | Ezetimibe | 50 | 12 |
| Promethazine Hcl | Promethazine Hcl | 48 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 48 | 11 |
| Trulicity | Dulaglutide | 48 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 47 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 45 | suppressed |
| Colchicine | Colchicine | 44 | 15 |
| Linzess | Linaclotide | 44 | 11 |
| Prednisone | Prednisone | 44 | 24 |
| Dexlansoprazole Dr | Dexlansoprazole | 43 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 43 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 40 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | suppressed |
| Xarelto | Rivaroxaban | 39 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 14 |
| Topiramate | Topiramate | 38 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 37 | 12 |
| Fenofibrate | Fenofibrate | 37 | 12 |
| Lansoprazole | Lansoprazole | 37 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 33 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Glipizide Er | Glipizide | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 35 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 14 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 33 | suppressed |
| Ramipril | Ramipril | 33 | 11 |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Fluconazole | Fluconazole | 32 | 21 |
| Mirtazapine | Mirtazapine | 32 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 27 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 30 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 29 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Mounjaro | Tirzepatide | 29 | suppressed |
| Mupirocin | Mupirocin | 29 | 19 |
| Cilostazol | Cilostazol | 28 | suppressed |
| Gemfibrozil | Gemfibrozil | 28 | suppressed |
| Glipizide | Glipizide | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 28 | suppressed |
| Levofloxacin | Levofloxacin | 26 | 22 |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Celecoxib | Celecoxib | 25 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 25 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 24 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 24 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 24 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 22 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 21 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 21 | suppressed |
| Lovastatin | Lovastatin | 20 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 20 | suppressed |
| Valsartan | Valsartan | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 13 |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | suppressed |
| Felodipine Er | Felodipine | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Nexium | Esomeprazole Magnesium | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Pitavastatin Calcium | Pitavastatin Calcium | 14 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 13 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 13 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 12 | suppressed |
| Carbamazepine Er | Carbamazepine | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | 11 |
| Estradiol | Estradiol | 12 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $904.28 · 46 records | Dexcom, Inc. | AREXVY, Arikayce, Brinsupri, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, General - Pain Management, KRYSTEXXA, LEQVIO, MOUNJARO, NUCALA, Ozempic, RELISTOR, SHINGRIX, Wegovy, ZEVTERA | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error